Literature DB >> 1876801

A quasi-exact test for comparing two binomial proportions.

K F Hirji1, S J Tan, R M Elashoff.   

Abstract

The use of the Fisher exact test for comparing two independent binomial proportions has spawned an extensive controversy in the statistical literature. Many critics have faulted this test for being highly conservative. Partly in response to such criticism, some statisticians have suggested the use of a modified, non-randomized version of this test, namely the mid-P-value test. This paper examines the actual type I error rates of this test. For both one-sided and two-sided tests, and for a wide range of sample sizes, we show that the actual levels of significance of the mid-P-test tend to be closer to the nominal level as compared with various classical tests. The computational effort required for the mid-P-test is no more than that needed for the Fisher exact test. Further, the basis for its modification is a natural adjustment for discreteness; thus the test easily generalizes to r x c contingency tables and other discrete data problems.

Entities:  

Mesh:

Year:  1991        PMID: 1876801     DOI: 10.1002/sim.4780100713

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  4 in total

1.  Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.

Authors:  Liza C Villaruz; Mark A Socinski; Shira Abberbock; Lynne D Berry; Bruce E Johnson; David J Kwiatkowski; A John Iafrate; Marileila Varella-Garcia; Wilbur A Franklin; D Ross Camidge; Lecia V Sequist; Eric B Haura; Mark Ladanyi; Brenda F Kurland; Kelly Kugler; John D Minna; Paul A Bunn; Mark G Kris
Journal:  Cancer       Date:  2014-10-01       Impact factor: 6.860

2.  Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.

Authors:  Eve T Rodler; Brenda F Kurland; Melissa Griffin; Julie R Gralow; Peggy Porter; Rosa F Yeh; Vijayakrishna K Gadi; Jamie Guenthoer; Jan H Beumer; Larissa Korde; Sandra Strychor; Brian F Kiesel; Hannah M Linden; John A Thompson; Elizabeth Swisher; Xiaoyu Chai; Stacie Shepherd; Vincent Giranda; Jennifer M Specht
Journal:  Clin Cancer Res       Date:  2016-01-22       Impact factor: 12.531

3.  18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study.

Authors:  Perrin E Romine; Lanell M Peterson; Brenda F Kurland; Darrin W Byrd; Alena Novakova-Jiresova; Mark Muzi; Jennifer M Specht; Robert K Doot; Jeanne M Link; Kenneth A Krohn; Paul E Kinahan; David A Mankoff; Hannah M Linden
Journal:  Breast Cancer Res       Date:  2021-08-23       Impact factor: 6.466

4.  The McNemar test for binary matched-pairs data: mid-p and asymptotic are better than exact conditional.

Authors:  Morten W Fagerland; Stian Lydersen; Petter Laake
Journal:  BMC Med Res Methodol       Date:  2013-07-13       Impact factor: 4.615

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.